Sex-specific disease modifiers in juvenile myoclonic epilepsy.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 02 2022
21 02 2022
Historique:
received:
27
08
2021
accepted:
25
11
2021
entrez:
22
2
2022
pubmed:
23
2
2022
medline:
16
3
2022
Statut:
epublish
Résumé
Juvenile myoclonic epilepsy (JME) is a common idiopathic generalised epilepsy with variable seizure prognosis and sex differences in disease presentation. Here, we investigate the combined epidemiology of sex, seizure types and precipitants, and their influence on prognosis in JME, through cross-sectional data collected by The Biology of Juvenile Myoclonic Epilepsy (BIOJUME) consortium. 765 individuals met strict inclusion criteria for JME (female:male, 1.8:1). 59% of females and 50% of males reported triggered seizures, and in females only, this was associated with experiencing absence seizures (OR = 2.0, p < 0.001). Absence seizures significantly predicted drug resistance in both males (OR = 3.0, p = 0.001) and females (OR = 3.0, p < 0.001) in univariate analysis. In multivariable analysis in females, catamenial seizures (OR = 14.7, p = 0.001), absence seizures (OR = 6.0, p < 0.001) and stress-precipitated seizures (OR = 5.3, p = 0.02) were associated with drug resistance, while a photoparoxysmal response predicted seizure freedom (OR = 0.47, p = 0.03). Females with both absence seizures and stress-related precipitants constitute the prognostic subgroup in JME with the highest prevalence of drug resistance (49%) compared to females with neither (15%) and males (29%), highlighting the unmet need for effective, targeted interventions for this subgroup. We propose a new prognostic stratification for JME and suggest a role for circuit-based risk of seizure control as an avenue for further investigation.
Identifiants
pubmed: 35190554
doi: 10.1038/s41598-022-06324-2
pii: 10.1038/s41598-022-06324-2
pmc: PMC8861057
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2785Subventions
Organisme : Medical Research Council
ID : MR/K013998/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N026063/1
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s).
Références
Pharmacol Ther. 2019 Sep;201:77-93
pubmed: 31128154
Epilepsia. 2005 Apr;46(4):517-23
pubmed: 15816945
Epilepsy Behav. 2013 Jul;28 Suppl 1:S15-7
pubmed: 23756473
J Neurosci. 1993 Sep;13(9):3839-47
pubmed: 8396170
Epilepsia. 2001 Mar;42(3):393-7
pubmed: 11442158
Neuroimage Clin. 2014 Nov 27;7:98-104
pubmed: 25610771
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Brain. 2006 May;129(Pt 5):1269-80
pubmed: 16520331
J Neurol Neurosurg Psychiatry. 1986 Dec;49(12):1386-91
pubmed: 3806115
Ann Neurol. 2002 May;51(5):599-603
pubmed: 12112106
Acta Neurol Scand. 2003 May;107(5):356-62
pubmed: 12713528
Eur J Neurol. 2019 Jun;26(6):856-864
pubmed: 30223294
Neuron. 2012 Sep 6;75(5):747-61
pubmed: 22958817
Brain Dev. 2006 Mar;28(2):92-8
pubmed: 16414227
Ann Clin Transl Neurol. 2021 Jan;8(1):138-152
pubmed: 33264519
Epilepsia. 2018 Jan;59(1):179-189
pubmed: 29124726
Neurology. 2009 Sep 29;73(13):1041-5
pubmed: 19786695
Nat Rev Neurosci. 2009 Jun;10(6):410-22
pubmed: 19455173
Epilepsia. 2012 Jan;53(1):16-24
pubmed: 22091642
Seizure. 2005 Jul;14(5):340-6
pubmed: 15955714
Seizure. 2018 Nov;62:17-25
pubmed: 30248569
Epilepsy Behav. 2017 Mar;68:225-233
pubmed: 28215998
Brain. 2016 Jun;139(Pt 6):1673-9
pubmed: 27036410
Neurology. 2012 May 15;78(20):1555-9
pubmed: 22551729
Ann Neurol. 2001 Mar;49(3):328-35
pubmed: 11261507
Curr Neurol Neurosci Rep. 2017 May;17(5):42
pubmed: 28382495
Neurology. 2020 Oct 13;95(15):e2150-e2160
pubmed: 32759205
Epilepsy Behav. 2013 Jul;28 Suppl 1:S87-90
pubmed: 23756490
Epilepsia. 2014 Jul;55(7):1038-47
pubmed: 24861441
Epilepsia. 2015 Jul;56(7):1006-19
pubmed: 25851171
Front Behav Neurosci. 2013 Feb 15;7:10
pubmed: 23422934
Clin Neurophysiol. 2004 May;115(5):1063-8
pubmed: 15066531
Lancet Neurol. 2017 Jan;16(1):76-87
pubmed: 27836433
Brain. 2011 Jun;134(Pt 6):1710-9
pubmed: 21616969
Brain. 2015 Aug;138(Pt 8):2234-48
pubmed: 26049086
Seizure. 2013 Oct;22(8):662-9
pubmed: 23746624
Epilepsia. 2005 Jun;46(6):956-60
pubmed: 15946339
Epilepsy Behav. 2013 Jul;28 Suppl 1:S25-9
pubmed: 23756476
Brain. 2020 Aug 1;143(8):2341-2368
pubmed: 32437558
Epilepsia. 2018 Nov;59(11):2086-2095
pubmed: 30281148
Epilepsy Behav. 2005 Feb;6(1):85-9
pubmed: 15652738
Hum Brain Mapp. 2013 Aug;34(8):1896-909
pubmed: 22431268
Seizure. 2015 Nov;32:62-8
pubmed: 26552565
Epilepsy Behav. 2014 Sep;38:160-71
pubmed: 24144618
Seizure. 2021 Mar;86:41-48
pubmed: 33524768
Epilepsy Behav. 2014 Apr;33:101-5
pubmed: 24632482
Brain. 2018 Oct 1;141(10):2981-2994
pubmed: 30169608
Seizure. 2008 Jun;17(4):302-7
pubmed: 17977026
J Neurol Sci. 2013 Jan 15;324(1-2):113-7
pubmed: 23149265